Streetbeat News

Price Targets

SITE

Truist Securities analyst Keith Hughes has maintained a 'Buy' rating on SiteOne Landscape Supply (NYSE:SITE) but lowered the price target from $187 to $158.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:08 pm

RPD

Truist Securities analyst Joel Fishbein maintains a 'Hold' rating on Rapid7 (NASDAQ:RPD) and raises the price target from $40 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:06 pm

CHCT

Piper Sandler analyst Alexander Goldfarb maintains an Overweight rating on Community Healthcare (NYSE:CHCT) but lowers the price target from $50 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:06 pm

PYPL

Truist Securities analyst Andrew Jeffrey maintains a 'Buy' rating on PayPal Holdings (NASDAQ:PYPL) but lowers the price target from $70 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:05 pm

TNDM

Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $40 to $25.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:04 pm

PSN

Truist Securities analyst Tobey Sommer maintains a 'Buy' rating on Parsons Corp (NYSE:PSN) and raises the price target from $66 to $74.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:03 pm

STAA

Piper Sandler analyst Matt O'Brien has maintained a Neutral rating on Staar Surgical (NASDAQ:STAA) and lowered the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:02 pm

OI

Truist Securities analyst Michael Roxland has maintained a 'Buy' rating on O-I Glass (NYSE:OI) but lowered the price target from $31 to $21.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:01 pm

BMRN

Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $125 to $115.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:00 pm

NVRO

Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Nevro (NYSE:NVRO) and lowers the price target from $18.5 to $17.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 7:59 pm